Sangamo Therapeutics, Inc. is a clinical-stage biotechnology firm headquartered in Brisbane, California, specializing in the development of transformative genomic medicines. Utilizing its innovative platform technologies in gene therapy, cell therapy, genome editing, and genome regulation, Sangamo is dedicated to addressing unmet medical needs and improving patient outcomes. The company's cutting-edge research focuses on advancing therapies for genetic and acquired diseases, positioning it as a pivotal player in the fast-evolving landscape of genomic medicine.